Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Jan den Hartigh"'
Autor:
Marion Rietveld, Jan W. Drijfhout, Alwin E. Adriaans, Peter H. Nibbering, Kirsten J. M. Schimmel, Robert A. Cordfunke, Suzan Commandeur, Sarah Zwart, Abdoelwaheb El Ghalbzouri, Elisabeth M. Haisma, Anikó Göblyös, Bep Ravensbergen, Jan den Hartigh, Remko van Leeuwen
Publikováno v:
International Journal of Antimicrobial Agents, 54(5), 610-618. ELSEVIER
Skin bacterial colonization/infection is a frequent cause of morbidity in patients with chronic wounds and allergic/inflammatory skin diseases. This study aimed to develop a novel approach to eradicate meticillin-resistant Staphylococcus aureus (MRSA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1d989a7219782a5a850e344b063d61
http://hdl.handle.net/1887/122411
http://hdl.handle.net/1887/122411
Autor:
Hester Ettaieb, Henk-Jan Guchelaar, Hans Gelderblom, T M A Kerkhofs, Kees Neef, Luc J J Derijks, Harm R. Haak, Jan den Hartigh
Publikováno v:
Therapeutic Drug Monitoring, 37(1), 58-65
Therapeutic Drug Monitoring, 37(1), 58-65. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 37(1), 58-65. LIPPINCOTT WILLIAMS & WILKINS
Background: Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma. The antineoplastic effect seems to be correlated with a minimum plasma level of 14 mg/L, but plasma concentration build-up is in general slow due to the long
Publikováno v:
Drug Discovery Today, 20, 18-36
Drug Discovery Today, 20(1), 18-36
Drug Discovery Today, 20, 1, pp. 18-36
Drug Discovery Today, 20(1), 18-36
Drug Discovery Today, 20, 1, pp. 18-36
Item does not contain fulltext Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral dose, despite their large variability in pharmacokinetics (PK). Given that the evidence for a relation between drug exposure and treatment outcome is grow
Publikováno v:
Antimicrobial Agents and Chemotherapy, 61, e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61, 9, pp. e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61(9)
Antimicrobial Agents & Chemotherapy, 61(9):e00267-17. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 61, 9, pp. e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61(9)
Antimicrobial Agents & Chemotherapy, 61(9):e00267-17. American Society for Microbiology
The lack of new antibiotics has prompted investigation of the combination of two existing agents—cefepime, a broad-spectrum cephalosporin, and tazobactam—to broaden their efficacy against extended-spectrum beta-lactamase (ESBL)-producing Enteroba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771e13a23e3e38ef0663ca00fbaaa3c1
https://doi.org/10.1128/AAC.00267-17
https://doi.org/10.1128/AAC.00267-17
Autor:
Rogier R. Press, Serge Cremers, Andrzej Baranski, P. Langers, Jan den Hartigh, Bart van Hoek, Akin Inderson
Publikováno v:
Therapeutic Drug Monitoring, 36(2), 141-147
The immunosuppressive drug mycophenolate mofetil (MMF), with mycophenolic acid (MPA) as active metabolite, is a nonnephrotoxic alternative to calcineurin inhibitors. Therapeutic drug monitoring (TDM) of MPA may improve clinical benefit from MMF thera
Autor:
Trees J. Hessing, Djoeke de Wit, Nielka P. van Erp, Hans Gelderblom, Henk-Jan Guchelaar, Jan den Hartigh
Publikováno v:
Journal of Chromatography. B, 937, pp. 33-43
Journal of Chromatography. B, 937, 33-43
Journal of Chromatography B, 937, 33-43
Journal of Chromatography. B, 937, 33-43
Journal of Chromatography B, 937, 33-43
Item does not contain fulltext A sensitive, sophisticated and practical bioanalytical assay for the simultaneous determination of six tyrosine kinase inhibitors (imatinib, sunitinib, nilotinib, dasatinib, pazopanib, regorafenib) and two active metabo
Autor:
Jan den Hartigh, Anikó Göblyös, Pieter S. Hiemstra, Kirsten J. M. Schimmel, Robert A. Cordfunke, A. Rob P. M. Valentijn, Jaap Oostendorp, Hee Lam Chan, Lorainne M. Fathers, Jan W. Drijfhout, Peter H. Nibbering
Publikováno v:
Journal of Pharmaceutical Sciences, 102(10), 3539-3544
Methicillin-resistant Staphylococcus aureus (MRSA) infections are an increasing problem, and current treatment options are suboptimal. Nasal carriage of MRSA is a major risk factor for infection, but nasal eradication strategies are increasingly cons
Autor:
Jan den Hartigh, Jan W. Drijfhout, Anikó Göblyös, Elisabeth M. Haisma, Ronald W. A. L. Limpens, Peter H. Nibbering, Abdoelwaheb El Ghalbzouri, Jasmijn A. Schrumpf, Robert A. Cordfunke, Kirsten J. M. Schimmel, Bep Ravensbergen, Pieter S. Hiemstra, Alwin E Adriaans
Publikováno v:
Antimicrobial Agents and Chemotherapy, 60(7), 4063-4072. AMER SOC MICROBIOLOGY
Antimicrobial Agents and Chemotherapy, 60(7), 4063-4072
Antimicrobial Agents and Chemotherapy, 60(7), 4063-4072
We previously found the LL-37-derived peptide P60.4Ac to be effective against methicillin-resistant Staphylococcus aureus (MRSA) on human epidermal models (EMs). The goal of this study was to identify the preferred carrier for this peptide for topica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44cbca0d2fc41c35d076f2de67559b8f
https://hdl.handle.net/1887/99322
https://hdl.handle.net/1887/99322
Autor:
Angela Colbers, Floor J E Lubberman, Hans Gelderblom, Winette T. A. van der Graaf, Peter F.A. Mulders, David M. Burger, Nielka P. van Erp, Saskia A C Luelmo, Jan den Hartigh, Carla M.L. van Herpen, Frank G A Jansman
Publikováno v:
Journal of Clinical Oncology, 34(15). AMER SOC CLINICAL ONCOLOGY
11040Background: Pazopanib has been registered for advanced soft tissue sarcoma (STS) and metastatic renal cell carcinoma (mRCC) and is used at a fixed oral dose of 800 mg taken fasted. However, ingesting pazopanib with food is a more patient friendl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1295388efbd4ed5bd79c2893189efb4
https://research.rug.nl/en/publications/b713ef5d-68f4-45e6-946a-01e314b1d275
https://research.rug.nl/en/publications/b713ef5d-68f4-45e6-946a-01e314b1d275
Autor:
Maarten Swartjes, Koen van de Wetering, Jos H Beijnen, Albert Dahan, Amanda R. Waxman, Jan den Hartigh, Caroline A. Arout, Benjamin Kest, René Mooren
Publikováno v:
Molecular Medicine. 18:1320-1326
Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain perception that may manifest during opioid treatment. For morphine, the metabolite morphine-3-glucuronide (M3G) is commonly believed to underlie this phenomenon. Here, in three separ